<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35353232</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1432-1459</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>269</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of neurology</Title>
          <ISOAbbreviation>J Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Neuroimmune disorders in COVID-19.</ArticleTitle>
        <Pagination>
          <StartPage>2827</StartPage>
          <EndPage>2839</EndPage>
          <MedlinePgn>2827-2839</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-022-11050-w</ELocationID>
        <Abstract>
          <AbstractText>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the aetiologic agent of the coronavirus disease 2019 (COVID-19), is now rapidly disseminating throughout the world with 147,443,848 cases reported so far. Around 30-80% of cases (depending on COVID-19 severity) are reported to have neurological manifestations including anosmia, stroke, and encephalopathy. In addition, some patients have recognised autoimmune neurological disorders, including both central (limbic and brainstem encephalitis, acute disseminated encephalomyelitis [ADEM], and myelitis) and peripheral diseases (Guillain-Barré and Miller Fisher syndrome). We systematically describe data from 133 reported series on the Neurology and Neuropsychiatry of COVID-19 blog ( https://blogs.bmj.com/jnnp/2020/05/01/the-neurology-and-neuropsychiatry-of-covid-19/ ) providing a comprehensive overview concerning the diagnosis, and treatment of patients with neurological immune-mediated complications of SARS-CoV-2. In most cases the latency to neurological disorder was highly variable and the immunological or other mechanisms involved were unclear. Despite specific neuronal or ganglioside antibodies only being identified in 10, many had apparent responses to immunotherapies. Although the proportion of patients experiencing immune-mediated neurological disorders is small, the total number is likely to be underestimated. The early recognition and improvement seen with use of immunomodulatory treatment, even in those without identified autoantibodies, makes delayed or missed diagnoses risk the potential for long-term disability, including the emerging challenge of post-acute COVID-19 sequelae (PACS). Finally, potential issues regarding the use of immunotherapies in patients with pre-existent neuro-immunological disorders are also discussed.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ariño</LastName>
            <ForeName>Helena</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0003-4036-1671</Identifier>
            <AffiliationInfo>
              <Affiliation>Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Heartshorne</LastName>
            <ForeName>Rosie</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Michael</LastName>
            <ForeName>Benedict D</ForeName>
            <Initials>BD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The National Institute for Health Research Health Protection Research Unit for Emerging and Zoonotic Infections, University of Liverpool, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Infection Microbiology and Immunology, Institute of Infection, Veterinary, and Ecological Sciences, University of Liverpool, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nicholson</LastName>
            <ForeName>Timothy R</ForeName>
            <Initials>TR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vincent</LastName>
            <ForeName>Angela</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pollak</LastName>
            <ForeName>Thomas A</ForeName>
            <Initials>TA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. thomas.pollak@kcl.ac.uk.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vogrig</LastName>
            <ForeName>Alberto</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Centre de Référence National pour les Syndromes Neurologiques Paranéoplasique, Hôpital Neurologique, Hospices Civils de Lyon, Lyon, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Clinical Neurology Unit, Azienda Sanitaria Universitaria Friuli Centrale, Presidio Ospedaliero Santa Maria Della Misericordia, Udine, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <Acronym>WT_</Acronym>
            <Agency>Wellcome Trust</Agency>
            <Country>United Kingdom</Country>
          </Grant>
          <Grant>
            <GrantID>ISSF201902/3</GrantID>
            <Acronym>WT_</Acronym>
            <Agency>Wellcome Trust</Agency>
            <Country>United Kingdom</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Neurol</MedlineTA>
        <NlmUniqueID>0423161</NlmUniqueID>
        <ISSNLinking>0340-5354</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020275" MajorTopicYN="Y">Guillain-Barre Syndrome</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009422" MajorTopicYN="Y">Nervous System Diseases</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020521" MajorTopicYN="Y">Stroke</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Autoimmune encephalitis</Keyword>
        <Keyword MajorTopicYN="N">Guillain–Barre syndrome</Keyword>
        <Keyword MajorTopicYN="N">Limbic encephalitis</Keyword>
        <Keyword MajorTopicYN="N">Neuroimmunology</Keyword>
        <Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
      </KeywordList>
      <CoiStatement>No other disclosures were reported.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>30</Day>
          <Hour>12</Hour>
          <Minute>15</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35353232</ArticleId>
        <ArticleId IdType="pmc">PMC9120100</ArticleId>
        <ArticleId IdType="doi">10.1007/s00415-022-11050-w</ArticleId>
        <ArticleId IdType="pii">10.1007/s00415-022-11050-w</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Liotta EM, Batra A, Clark JR, et al.  Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients. Ann Clin Transl Neurol. 2020;7:2221–2230. doi: 10.1002/acn3.51210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/acn3.51210</ArticleId>
            <ArticleId IdType="pmc">PMC7664279</ArticleId>
            <ArticleId IdType="pubmed">33016619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pun BT, Badenes R, Heras La Calle G, et al.  Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): a multicentre cohort study. Lancet Respir Med. 2021;9:239–250. doi: 10.1016/S2213-2600(20)30552-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2213-2600(20)30552-X</ArticleId>
            <ArticleId IdType="pmc">PMC7832119</ArticleId>
            <ArticleId IdType="pubmed">33428871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Helms J, Kremer S, Merdji H, et al.  Delirium and encephalopathy in severe COVID-19: a cohort analysis of ICU patients. Crit Care. 2020;24:491. doi: 10.1186/s13054-020-03200-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13054-020-03200-1</ArticleId>
            <ArticleId IdType="pmc">PMC7414289</ArticleId>
            <ArticleId IdType="pubmed">32771053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao L, Jin H, Wang M, et al.  Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77:683–690. doi: 10.1001/jamaneurol.2020.1127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2020.1127</ArticleId>
            <ArticleId IdType="pmc">PMC7149362</ArticleId>
            <ArticleId IdType="pubmed">32275288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taquet M, Geddes JR, Husain M, et al.  6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021 doi: 10.1016/S2215-0366(21)00084-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2215-0366(21)00084-5</ArticleId>
            <ArticleId IdType="pmc">PMC8216633</ArticleId>
            <ArticleId IdType="pubmed">34147175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varatharaj A, Thomas N, Ellul M, et al.  UK-wide surveillance of neurological and neuropsychiatric complications of COVID-19: the first 153 patients. Lancet Psychiatry. 2020;7:875–882. doi: 10.1016/S2215-0366(20)30287-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2215-0366(20)30287-X</ArticleId>
            <ArticleId IdType="pmc">PMC7316461</ArticleId>
            <ArticleId IdType="pubmed">32593341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ellul M, Varatharaj A, Nicholson TR, et al.  Defining causality in COVID-19 and neurological disorders. J Neurol Neurosurg Psychiatry. 2020;91:811–812. doi: 10.1136/jnnp-2020-323667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2020-323667</ArticleId>
            <ArticleId IdType="pmc">PMC7299654</ArticleId>
            <ArticleId IdType="pubmed">32503883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iadecola C, Anrather J, Kamel H. Effects of COVID-19 on the nervous system. Cell. 2020;183:16–27.e1. doi: 10.1016/j.cell.2020.08.028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2020.08.028</ArticleId>
            <ArticleId IdType="pmc">PMC7437501</ArticleId>
            <ArticleId IdType="pubmed">32882182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kreye J, Reincke SM, Kornau H-C, et al.  A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model. Cell. 2020;183:1058–1069.e19. doi: 10.1016/j.cell.2020.09.049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2020.09.049</ArticleId>
            <ArticleId IdType="pmc">PMC7510528</ArticleId>
            <ArticleId IdType="pubmed">33058755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franke C, Ferse C, Kreye J, et al.  High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. Brain Behav Immun. 2021;93:415–419. doi: 10.1016/j.bbi.2020.12.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbi.2020.12.022</ArticleId>
            <ArticleId IdType="pmc">PMC7834471</ArticleId>
            <ArticleId IdType="pubmed">33359380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zuo Y, Estes SK, Ali RA, et al.  Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med. 2020 doi: 10.1126/scitranslmed.abd3876.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.abd3876</ArticleId>
            <ArticleId IdType="pmc">PMC7724273</ArticleId>
            <ArticleId IdType="pubmed">33139519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang EY, Mao T, Klein J, et al.  Diverse functional autoantibodies in patients with COVID-19. medRxiv Prepr Serv Heal Sci. 2020 doi: 10.1101/2020.12.10.20247205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2020.12.10.20247205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Titulaer MJ, Balu R, et al.  A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15:391–404. doi: 10.1016/S1474-4422(15)00401-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(15)00401-9</ArticleId>
            <ArticleId IdType="pmc">PMC5066574</ArticleId>
            <ArticleId IdType="pubmed">26906964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong AM, Simon EM, Zimmerman RA, et al.  Acute necrotizing encephalopathy of childhood: correlation of MR findings and clinical outcome. AJNR Am J Neuroradiol. 2006;27:1919–1923.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7977901</ArticleId>
            <ArticleId IdType="pubmed">17032866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fokke C, van den Berg B, Drenthen J, et al.  Diagnosis of Guillain–Barré syndrome and validation of Brighton criteria. Brain. 2014;137:33–43. doi: 10.1093/brain/awt285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awt285</ArticleId>
            <ArticleId IdType="pubmed">24163275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matschke J, Lütgehetmann M, Hagel C, et al.  Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 2020;19:919–929. doi: 10.1016/S1474-4422(20)30308-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(20)30308-2</ArticleId>
            <ArticleId IdType="pmc">PMC7535629</ArticleId>
            <ArticleId IdType="pubmed">33031735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varga Z, Flammer AJ, Steiger P, et al.  Endothelial cell infection and endotheliitis in COVID-19. Lancet (Lond, Engl) 2020;395:1417–1418. doi: 10.1016/S0140-6736(20)30937-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(20)30937-5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383:2255–2273. doi: 10.1056/NEJMra2026131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra2026131</ArticleId>
            <ArticleId IdType="pmc">PMC7727315</ArticleId>
            <ArticleId IdType="pubmed">33264547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>RECOVERY Collaborative Group  Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet (Lond, Engl) 2021;397:1637–1645. doi: 10.1016/S0140-6736(21)00676-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(21)00676-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalil AC, Patterson TF, Mehta AK, et al.  Baricitinib plus remdesivir for hospitalized adults with covid-19. N Engl J Med. 2021;384:795–807. doi: 10.1056/NEJMoa2031994.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2031994</ArticleId>
            <ArticleId IdType="pmc">PMC7745180</ArticleId>
            <ArticleId IdType="pubmed">33306283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pilotto A, Masciocchi S, Volonghi I, et al.  SARS-CoV-2 encephalitis is a cytokine release syndrome: evidences from cerebrospinal fluid analyses. Clin Infect Dis. 2021 doi: 10.1093/cid/ciaa1933.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciaa1933</ArticleId>
            <ArticleId IdType="pmc">PMC7799260</ArticleId>
            <ArticleId IdType="pubmed">33395482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexopoulos H, Magira E, Bitzogli K, et al.  Anti-SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome: studies in 8 stuporous and comatose patients. Neurol Neuroimmunol Neuroinflamm. 2020 doi: 10.1212/NXI.0000000000000893.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000893</ArticleId>
            <ArticleId IdType="pmc">PMC7577546</ArticleId>
            <ArticleId IdType="pubmed">32978291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bodro M, Compta Y, Llansó L, et al.  Increased CSF levels of IL-1β, IL-6, and ACE in SARS-CoV-2-associated encephalitis. Neurol Neuroimmunol Neuroinflamm. 2020 doi: 10.1212/NXI.0000000000000821.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000821</ArticleId>
            <ArticleId IdType="pmc">PMC7808129</ArticleId>
            <ArticleId IdType="pubmed">33310765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song E, Bartley CM, Chow RD, et al.  Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms. Cell Rep Med. 2021 doi: 10.1016/j.xcrm.2021.100288.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.xcrm.2021.100288</ArticleId>
            <ArticleId IdType="pmc">PMC8536523</ArticleId>
            <ArticleId IdType="pubmed">34723223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ellul MA, Benjamin L, Singh B, et al.  Neurological associations of COVID-19. Lancet Neurol. 2020;19:767–783. doi: 10.1016/S1474-4422(20)30221-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(20)30221-0</ArticleId>
            <ArticleId IdType="pmc">PMC7332267</ArticleId>
            <ArticleId IdType="pubmed">32622375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ross Russell A, Hardwick M, Jeyanantham A, et al.  Spectrum, risk factors, and outcomes of neurological and psychiatric complications of COVID-19: a UK-wide cross-sectional surveillance study. SSRN Electron J. 2021 doi: 10.2139/ssrn.3767901.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2139/ssrn.3767901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paterson RW, Brown RL, Benjamin L, et al.  The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain. 2020;143:3104–3120. doi: 10.1093/brain/awaa240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awaa240</ArticleId>
            <ArticleId IdType="pmc">PMC7454352</ArticleId>
            <ArticleId IdType="pubmed">32637987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pilotto A, Masciocchi S, Volonghi I, et al.  The clinical spectrum of encephalitis in COVID-19 disease: the ENCOVID multicentre study. medRxiv. 2020 doi: 10.1101/2020.06.19.20133991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2020.06.19.20133991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muccioli L, Pensato U, Bernabè G, et al.  Intravenous immunoglobulin therapy in COVID-19-related encephalopathy. J Neurol. 2020 doi: 10.1007/s00415-020-10248-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-020-10248-0</ArticleId>
            <ArticleId IdType="pmc">PMC7543032</ArticleId>
            <ArticleId IdType="pubmed">33030607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kihira S, Delman BN, Belani P, et al.  imaging features of acute encephalopathy in patients with COVID-19: a case series. AJNR Am J Neuroradiol. 2020;41:1804–1808. doi: 10.3174/ajnr.A6715.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3174/ajnr.A6715</ArticleId>
            <ArticleId IdType="pmc">PMC7661067</ArticleId>
            <ArticleId IdType="pubmed">32816764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao A, Rohaut B, Le Guennec L, et al.  Severe COVID-19-related encephalitis can respond to immunotherapy. Brain. 2020;143:e102. doi: 10.1093/brain/awaa337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awaa337</ArticleId>
            <ArticleId IdType="pmc">PMC7665364</ArticleId>
            <ArticleId IdType="pubmed">33064794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dogan L, Kaya D, Sarikaya T, et al.  Plasmapheresis treatment in COVID-19-related autoimmune meningoencephalitis: case series. Brain Behav Immun. 2020;87:155–158. doi: 10.1016/j.bbi.2020.05.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbi.2020.05.022</ArticleId>
            <ArticleId IdType="pmc">PMC7204750</ArticleId>
            <ArticleId IdType="pubmed">32389697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perrin P, Collongues N, Baloglu S, et al.  Cytokine release syndrome-associated encephalopathy in patients with COVID-19. Eur J Neurol. 2021;28:248–258. doi: 10.1111/ene.14491.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ene.14491</ArticleId>
            <ArticleId IdType="pmc">PMC7461405</ArticleId>
            <ArticleId IdType="pubmed">32853434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Helms J, Kremer S, Merdji H, et al.  Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020;382:2268–2270. doi: 10.1056/NEJMc2008597.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc2008597</ArticleId>
            <ArticleId IdType="pmc">PMC7179967</ArticleId>
            <ArticleId IdType="pubmed">32294339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grzonka P, Scholz MC, De Marchis GM, et al.  Acute hemorrhagic leukoencephalitis: a case and systematic review of the literature. Front Neurol. 2020;11:899. doi: 10.3389/fneur.2020.00899.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2020.00899</ArticleId>
            <ArticleId IdType="pmc">PMC7468463</ArticleId>
            <ArticleId IdType="pubmed">32973663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pugin D, Vargas M-I, Thieffry C, et al.  COVID-19-related encephalopathy responsive to high-dose glucocorticoids. Neurology. 2020;95:543–546. doi: 10.1212/WNL.0000000000010354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000010354</ArticleId>
            <ArticleId IdType="pubmed">32680950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Álvarez Bravo G, Ramió i Torrentà L. Encefalitis anti-NMDA-R secundaria a infección por SARS-CoV-2. Neurologia. 2020;35:699–700. doi: 10.1016/j.nrl.2020.07.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nrl.2020.07.013</ArticleId>
            <ArticleId IdType="pmc">PMC7546184</ArticleId>
            <ArticleId IdType="pubmed">32912742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burr T, Barton C, Doll E, et al.  N-Methyl-d-aspartate receptor encephalitis associated with COVID-19 infection in a Toddler. Pediatr Neurol. 2021;114:75–76. doi: 10.1016/j.pediatrneurol.2020.10.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pediatrneurol.2020.10.002</ArticleId>
            <ArticleId IdType="pmc">PMC7546658</ArticleId>
            <ArticleId IdType="pubmed">33246132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Monti G, Giovannini G, Marudi A, et al.  Anti-NMDA receptor encephalitis presenting as new onset refractory status epilepticus in COVID-19. Seizure. 2020;81:18–20. doi: 10.1016/j.seizure.2020.07.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.seizure.2020.07.006</ArticleId>
            <ArticleId IdType="pmc">PMC7362825</ArticleId>
            <ArticleId IdType="pubmed">32688169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Panariello A, Bassetti R, Radice A, et al.  Anti-NMDA receptor encephalitis in a psychiatric Covid-19 patient: a case report. Brain Behav Immun. 2020;87:179–181. doi: 10.1016/j.bbi.2020.05.054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbi.2020.05.054</ArticleId>
            <ArticleId IdType="pmc">PMC7255176</ArticleId>
            <ArticleId IdType="pubmed">32454137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarigecili E, Arslan I, Ucar HK, Celik U. Pediatric anti-NMDA receptor encephalitis associated with COVID-19. Childs Nerv Syst. 2021 doi: 10.1007/s00381-021-05155-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00381-021-05155-2</ArticleId>
            <ArticleId IdType="pmc">PMC8045445</ArticleId>
            <ArticleId IdType="pubmed">33852058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McHattie AW, Coebergh J, Khan F, Morgante F. Palilalia as a prominent feature of anti-NMDA receptor encephalitis in a woman with COVID-19. J Neurol. 2021 doi: 10.1007/s00415-021-10542-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-021-10542-5</ArticleId>
            <ArticleId IdType="pmc">PMC8027295</ArticleId>
            <ArticleId IdType="pubmed">33830334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sánchez-Morales AE, Urrutia-Osorio M, Camacho-Mendoza E, et al.  Neurological manifestations temporally associated with SARS-CoV-2 infection in pediatric patients in Mexico. Childs Nerv Syst. 2021;37:2305–2312. doi: 10.1007/s00381-021-05104-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00381-021-05104-z</ArticleId>
            <ArticleId IdType="pmc">PMC7943407</ArticleId>
            <ArticleId IdType="pubmed">33751228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allahyari F, Hosseinzadeh R, Nejad JH, et al.  A case report of simultaneous autoimmune and COVID-19 encephalitis. J Neurovirol. 2021;27:504–506. doi: 10.1007/s13365-021-00978-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13365-021-00978-w</ArticleId>
            <ArticleId IdType="pmc">PMC8075017</ArticleId>
            <ArticleId IdType="pubmed">33904138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guilmot A, Maldonado Slootjes S, Sellimi A, et al.  Immune-mediated neurological syndromes in SARS-CoV-2-infected patients. J Neurol. 2021;268:751–757. doi: 10.1007/s00415-020-10108-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-020-10108-x</ArticleId>
            <ArticleId IdType="pmc">PMC7391231</ArticleId>
            <ArticleId IdType="pubmed">32734353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pinto AA, Carroll LS, Nar V, et al.  CNS inflammatory vasculopathy with antimyelin oligodendrocyte glycoprotein antibodies in COVID-19. Neurol Neuroimmunol Neuroinflamm. 2020 doi: 10.1212/NXI.0000000000000813.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000813</ArticleId>
            <ArticleId IdType="pmc">PMC7309522</ArticleId>
            <ArticleId IdType="pubmed">32522768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mulder J, Feresiadou A, Fällmar D, et al.  Autoimmune encephalitis presenting with malignant catatonia in a 40-year-old male patient with COVID-19. Am J Psychiatry. 2021;178:485–489. doi: 10.1176/appi.ajp.2020.20081236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1176/appi.ajp.2020.20081236</ArticleId>
            <ArticleId IdType="pubmed">34154381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mulder J, Lindqvist I, Rasmusson AJ, et al.  Indirect immunofluorescence for detecting anti-neuronal autoimmunity in CSF after COVID-19—possibilities and pitfalls. Brain Behav Immun. 2021;94:473–474. doi: 10.1016/j.bbi.2021.02.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbi.2021.02.013</ArticleId>
            <ArticleId IdType="pubmed">33631284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Efe IE, Aydin OU, Alabulut A, et al.  COVID-19-associated encephalitis mimicking glial tumor. World Neurosurg. 2020;140:46–48. doi: 10.1016/j.wneu.2020.05.194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.wneu.2020.05.194</ArticleId>
            <ArticleId IdType="pmc">PMC7256557</ArticleId>
            <ArticleId IdType="pubmed">32479911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sriwastava S, Kataria S, Tandon M, et al.  Guillain Barré syndrome and its variants as a manifestation of COVID-19: a systematic review of case reports and case series. J Neurol Sci. 2021;420:117263. doi: 10.1016/j.jns.2020.117263.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2020.117263</ArticleId>
            <ArticleId IdType="pmc">PMC7725056</ArticleId>
            <ArticleId IdType="pubmed">33321326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filosto M, Cotti Piccinelli S, Gazzina S, et al.  Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions. J Neurol Neurosurg Psychiatry. 2021;92:751–756. doi: 10.1136/jnnp-2020-324837.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2020-324837</ArticleId>
            <ArticleId IdType="pmc">PMC7650204</ArticleId>
            <ArticleId IdType="pubmed">33158914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fragiel M, Miró Ò, Llorens P, et al.  Incidence, clinical, risk factors and outcomes of Guillain–Barré in Covid-19. Ann Neurol. 2021;89:598–603. doi: 10.1002/ana.25987.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.25987</ArticleId>
            <ArticleId IdType="pubmed">33295021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao H, Shen D, Zhou H, et al.  Guillain–Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol. 2020;19:383–384. doi: 10.1016/S1474-4422(20)30109-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(20)30109-5</ArticleId>
            <ArticleId IdType="pmc">PMC7176927</ArticleId>
            <ArticleId IdType="pubmed">32246917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keddie S, Pakpoor J, Mousele C, et al.  Epidemiological and cohort study finds no association between COVID-19 and Guillain–Barré syndrome. Brain. 2021;144:682–693. doi: 10.1093/brain/awaa433.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awaa433</ArticleId>
            <ArticleId IdType="pmc">PMC7799186</ArticleId>
            <ArticleId IdType="pubmed">33313649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao-Lormeau V-M, Blake A, Mons S, et al.  Guillain-Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet (Lond Engl) 2016;387:1531–1539. doi: 10.1016/S0140-6736(16)00562-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(16)00562-6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Islam B, Islam Z, GeurtsvanKessel CH, et al.  Guillain-Barré syndrome following varicella-zoster virus infection. Eur J Clin Microbiol Infect Dis. 2018;37:511–518. doi: 10.1007/s10096-018-3199-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10096-018-3199-5</ArticleId>
            <ArticleId IdType="pubmed">29411189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jackson BR, Zegarra JA, López-Gatell H, et al.  Binational outbreak of Guillain–Barré syndrome associated with Campylobacter jejuni infection, Mexico and USA, 2011. Epidemiol Infect. 2014;142:1089–1099. doi: 10.1017/S0950268813001908.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/S0950268813001908</ArticleId>
            <ArticleId IdType="pmc">PMC6527315</ArticleId>
            <ArticleId IdType="pubmed">23924442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garnero M, Del Sette M, Assini A, et al.  COVID-19-related and not related Guillain–Barré syndromes share the same management pitfalls during lock down: the experience of Liguria region in Italy. J Neurol Sci. 2020;418:117114. doi: 10.1016/j.jns.2020.117114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2020.117114</ArticleId>
            <ArticleId IdType="pmc">PMC7462770</ArticleId>
            <ArticleId IdType="pubmed">32947089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gutiérrez-Ortiz C, Méndez-Guerrero A, Rodrigo-Rey S, et al.  Miller Fisher syndrome and polyneuritis cranialis in COVID-19. Neurology. 2020;95:e601–e605. doi: 10.1212/WNL.0000000000009619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000009619</ArticleId>
            <ArticleId IdType="pubmed">32303650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Padroni M, Mastrangelo V, Asioli GM, et al.  Guillain–Barré syndrome following COVID-19: new infection, old complication? J Neurol. 2020;267:1877–1879. doi: 10.1007/s00415-020-09849-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-020-09849-6</ArticleId>
            <ArticleId IdType="pmc">PMC7180646</ArticleId>
            <ArticleId IdType="pubmed">32333166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toscano G, Palmerini F, Ravaglia S, et al.  Guillain–Barré syndrome associated with SARS-CoV-2. N Engl J Med. 2020;382:2574–2576. doi: 10.1056/NEJMc2009191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc2009191</ArticleId>
            <ArticleId IdType="pmc">PMC7182017</ArticleId>
            <ArticleId IdType="pubmed">32302082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnaud S, Budowski C, Ng Wing Tin S, Degos B. Post SARS-CoV-2 Guillain-Barré syndrome. Clin Neurophysiol. 2020;131:1652–1654. doi: 10.1016/j.clinph.2020.05.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinph.2020.05.003</ArticleId>
            <ArticleId IdType="pmc">PMC7212990</ArticleId>
            <ArticleId IdType="pubmed">32422529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su XW, Palka SV, Rao RR, et al.  SARS-CoV-2-associated Guillain–Barré syndrome with dysautonomia. Muscle Nerve. 2020;62:E48–E49. doi: 10.1002/mus.26988.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.26988</ArticleId>
            <ArticleId IdType="pmc">PMC7283744</ArticleId>
            <ArticleId IdType="pubmed">32445201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pfefferkorn T, Dabitz R, von Wernitz-Keibel T, et al.  Acute polyradiculoneuritis with locked-in syndrome in a patient with Covid-19. J Neurol. 2020;267:1883–1884. doi: 10.1007/s00415-020-09897-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-020-09897-y</ArticleId>
            <ArticleId IdType="pmc">PMC7216124</ArticleId>
            <ArticleId IdType="pubmed">32399694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bigaut K, Mallaret M, Baloglu S, et al.  Guillain-Barré syndrome related to SARS-CoV-2 infection. Neurol Neuroimmunol neuroinflammation. 2020 doi: 10.1212/NXI.0000000000000785.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oguz-Akarsu E, Ozpar R, Mirzayev H, et al.  Guillain–Barré syndrome in a patient with minimal symptoms of COVID-19 infection. Muscle Nerve. 2020;62:E54–E57. doi: 10.1002/mus.26992.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.26992</ArticleId>
            <ArticleId IdType="pmc">PMC7300697</ArticleId>
            <ArticleId IdType="pubmed">32497292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manganotti P, Bellavita G, D’Acunto L, et al.  Clinical neurophysiology and cerebrospinal liquor analysis to detect Guillain–Barré syndrome and polyneuritis cranialis in COVID-19 patients: a case series. J Med Virol. 2021;93:766–774. doi: 10.1002/jmv.26289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jmv.26289</ArticleId>
            <ArticleId IdType="pmc">PMC7405169</ArticleId>
            <ArticleId IdType="pubmed">32662899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Assini A, Benedetti L, Di Maio S, et al.  New clinical manifestation of COVID-19 related Guillain–Barrè syndrome highly responsive to intravenous immunoglobulins: two Italian cases. Neurol Sci. 2020;41:1657–1658. doi: 10.1007/s10072-020-04484-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10072-020-04484-5</ArticleId>
            <ArticleId IdType="pmc">PMC8849645</ArticleId>
            <ArticleId IdType="pubmed">32468450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sancho-Saldaña A, Lambea-Gil Á, Liesa JLC, et al.  Guillain–Barré syndrome associated with leptomeningeal enhancement following SARS-CoV-2 infection. Clin Med. 2020;20:e93–e94. doi: 10.7861/clinmed.2020-0213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7861/clinmed.2020-0213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alberti P, Beretta S, Piatti M, et al.  Guillain-Barré syndrome related to COVID-19 infection. Neurol Neuroimmunol neuroinflammation. 2020 doi: 10.1212/NXI.0000000000000741.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coen M, Jeanson G, Culebras Almeida LA, et al.  Guillain–Barré syndrome as a complication of SARS-CoV-2 infection. Brain Behav Immun. 2020;87:111–112. doi: 10.1016/j.bbi.2020.04.074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbi.2020.04.074</ArticleId>
            <ArticleId IdType="pmc">PMC7194931</ArticleId>
            <ArticleId IdType="pubmed">32360440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lascano AM, Epiney J-B, Coen M, et al.  SARS-CoV-2 and Guillain-Barré syndrome: AIDP variant with a favourable outcome. Eur J Neurol. 2020;27:1751–1753. doi: 10.1111/ene.14368.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ene.14368</ArticleId>
            <ArticleId IdType="pmc">PMC7300656</ArticleId>
            <ArticleId IdType="pubmed">32478936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gigli GL, Vogrig A, Nilo A, et al.  HLA and immunological features of SARS-CoV-2-induced Guillain–Barré syndrome. Neurol Sci. 2020;41:3391–3394. doi: 10.1007/s10072-020-04787-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10072-020-04787-7</ArticleId>
            <ArticleId IdType="pmc">PMC7530349</ArticleId>
            <ArticleId IdType="pubmed">33006723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scheidl E, Canseco DD, Hadji-Naumov A, Bereznai B. Guillain–Barré syndrome during SARS-CoV-2 pandemic: a case report and review of recent literature. J Peripher Nerv Syst. 2020;25:204–207. doi: 10.1111/jns.12382.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jns.12382</ArticleId>
            <ArticleId IdType="pmc">PMC7273104</ArticleId>
            <ArticleId IdType="pubmed">32388880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ottaviani D, Boso F, Tranquillini E, et al.  Early Guillain–Barré syndrome in coronavirus disease 2019 (COVID-19): a case report from an Italian COVID-hospital. Neurol Sci. 2020;41:1351–1354. doi: 10.1007/s10072-020-04449-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10072-020-04449-8</ArticleId>
            <ArticleId IdType="pmc">PMC7216127</ArticleId>
            <ArticleId IdType="pubmed">32399950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abolmaali M, Heidari M, Zeinali M, et al.  Guillain–Barré syndrome as a parainfectious manifestation of SARS-CoV-2 infection: a case series. J Clin Neurosci. 2021;83:119–122. doi: 10.1016/j.jocn.2020.11.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jocn.2020.11.013</ArticleId>
            <ArticleId IdType="pmc">PMC7666532</ArticleId>
            <ArticleId IdType="pubmed">33281050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes RA, Brassington R, Gunn AA, van Doorn PA. Corticosteroids for Guillain–Barré syndrome. Cochrane database Syst Rev. 2016;10:CD001446. doi: 10.1002/14651858.CD001446.pub5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/14651858.CD001446.pub5</ArticleId>
            <ArticleId IdType="pmc">PMC6464149</ArticleId>
            <ArticleId IdType="pubmed">27775812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manganotti P, Pesavento V, Buoite Stella A, et al.  Miller Fisher syndrome diagnosis and treatment in a patient with SARS-CoV-2. J Neurovirol. 2020;26:605–606. doi: 10.1007/s13365-020-00858-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13365-020-00858-9</ArticleId>
            <ArticleId IdType="pmc">PMC7288617</ArticleId>
            <ArticleId IdType="pubmed">32529516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Juliao Caamaño DS, Alonso Beato R. Facial diplegia, a possible atypical variant of Guillain–Barré Syndrome as a rare neurological complication of SARS-CoV-2. J Clin Neurosci. 2020;77:230–232. doi: 10.1016/j.jocn.2020.05.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jocn.2020.05.016</ArticleId>
            <ArticleId IdType="pmc">PMC7221378</ArticleId>
            <ArticleId IdType="pubmed">32410788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghiasvand F, Ghadimi M, Ghadimi F, et al.  Symmetrical polyneuropathy in coronavirus disease 2019 (COVID-19) IDCases. 2020;21:e00815. doi: 10.1016/j.idcr.2020.e00815.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.idcr.2020.e00815</ArticleId>
            <ArticleId IdType="pmc">PMC7255269</ArticleId>
            <ArticleId IdType="pubmed">32514394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leonhard SE, Mandarakas MR, Gondim FAA, et al.  Diagnosis and management of Guillain–Barré syndrome in ten steps. Nat Rev Neurol. 2019;15:671–683. doi: 10.1038/s41582-019-0250-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41582-019-0250-9</ArticleId>
            <ArticleId IdType="pmc">PMC6821638</ArticleId>
            <ArticleId IdType="pubmed">31541214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reyes-Bueno JA, García-Trujillo L, Urbaneja P, et al.  Miller–Fisher syndrome after SARS-CoV-2 infection. Eur J Neurol. 2020;27:1759–1761. doi: 10.1111/ene.14383.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ene.14383</ArticleId>
            <ArticleId IdType="pmc">PMC7300794</ArticleId>
            <ArticleId IdType="pubmed">32503084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fernández-Domínguez J, Ameijide-Sanluis E, García-Cabo C, et al.  Miller–Fisher-like syndrome related to SARS-CoV-2 infection (COVID 19) J Neurol. 2020;267:2495–2496. doi: 10.1007/s00415-020-09912-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-020-09912-2</ArticleId>
            <ArticleId IdType="pmc">PMC7249969</ArticleId>
            <ArticleId IdType="pubmed">32458195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taams NE, Notermans NC, Fokkink W-JR, et al.  Clinical relevance of serum antibodies to GD1b in immune-mediated neuropathies. J Peripher Nerv Syst. 2018;23:227–234. doi: 10.1111/jns.12285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jns.12285</ArticleId>
            <ArticleId IdType="pubmed">30101437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan M, Han SC, Kelly S, et al.  A case series of Guillain–Barré syndrome following covid-19 infection in New York. Neurol Clin Pract. 2020 doi: 10.1212/CPJ.0000000000000880.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/CPJ.0000000000000880</ArticleId>
            <ArticleId IdType="pmc">PMC7837440</ArticleId>
            <ArticleId IdType="pubmed">33510947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim JK, Kim YH, Yoon BA, et al.  Clinical heterogeneity of anti-GM2-ganglioside-antibody syndrome. J Clin Neurol. 2018;14:401–406. doi: 10.3988/jcn.2018.14.3.401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3988/jcn.2018.14.3.401</ArticleId>
            <ArticleId IdType="pmc">PMC6031993</ArticleId>
            <ArticleId IdType="pubmed">29971981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korsukewitz C, Reddel SW, Bar-Or A, Wiendl H. Neurological immunotherapy in the era of COVID-19—looking for consensus in the literature. Nat Rev Neurol. 2020;16:493–505. doi: 10.1038/s41582-020-0385-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41582-020-0385-8</ArticleId>
            <ArticleId IdType="pmc">PMC7341707</ArticleId>
            <ArticleId IdType="pubmed">32641860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Attauabi M, Seidelin JB, Felding OK, et al.  Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies—a Danish population-based cohort study. J Autoimmunity. 2021;118:102613. doi: 10.1016/j.jaut.2021.102613.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaut.2021.102613</ArticleId>
            <ArticleId IdType="pmc">PMC7879155</ArticleId>
            <ArticleId IdType="pubmed">33592545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barlow-Pay F, Htut TW, Khezrian M, Myint PK. Systematic review of immunosuppressant guidelines in the COVID-19 pandemic. Ther Adv Drug Saf. 2021 doi: 10.1177/2042098620985687.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/2042098620985687</ArticleId>
            <ArticleId IdType="pmc">PMC7897811</ArticleId>
            <ArticleId IdType="pubmed">33680426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sormani MP, De Rossi N, Schiavetti I, et al.  Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol. 2021;89:780–789. doi: 10.1002/ana.26028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.26028</ArticleId>
            <ArticleId IdType="pmc">PMC8013440</ArticleId>
            <ArticleId IdType="pubmed">33480077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>COVID-19 guidance and advice—Association of British Neurologists [online]. https://www.theabn.org/page/COVID-19</Citation>
        </Reference>
        <Reference>
          <Citation>Dalakas MC. Guillain-Barré syndrome: the first documented COVID-19-triggered autoimmune neurologic disease: more to come with myositis in the offing. Neurol Neuroimmunol Neuroinflamm. 2020 doi: 10.1212/NXI.0000000000000781.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000781</ArticleId>
            <ArticleId IdType="pmc">PMC7757781</ArticleId>
            <ArticleId IdType="pubmed">33411673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Schaik IN, Bril V, van Geloven N, et al.  Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2018;17:35–46. doi: 10.1016/S1474-4422(17)30378-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(17)30378-2</ArticleId>
            <ArticleId IdType="pubmed">29122523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maarouf A, Rico A, Boutiere C, et al.  Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond? Neurol Neuroimmunol Neuroinflamm. 2020 doi: 10.1212/NXI.0000000000000825.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000825</ArticleId>
            <ArticleId IdType="pmc">PMC7357416</ArticleId>
            <ArticleId IdType="pubmed">32587103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>RECOVERY Collaborative Group. Horby P, Lim WS, et al.  Dexamethasone in hospitalized patients with covid-19. N Engl J Med. 2021;384:693–704. doi: 10.1056/NEJMoa2021436.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId>
            <ArticleId IdType="pmc">PMC7383595</ArticleId>
            <ArticleId IdType="pubmed">32678530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morassi M, Bagatto D, Cobelli M, et al.  Stroke in patients with SARS-CoV-2 infection: case series. J Neurol. 2020;267:2185–2192. doi: 10.1007/s00415-020-09885-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-020-09885-2</ArticleId>
            <ArticleId IdType="pmc">PMC7238403</ArticleId>
            <ArticleId IdType="pubmed">32436105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39:405–407. doi: 10.1016/j.healun.2020.03.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.healun.2020.03.012</ArticleId>
            <ArticleId IdType="pmc">PMC7118652</ArticleId>
            <ArticleId IdType="pubmed">32362390</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
